Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
November 2024
The global hemoglobin A1c testing devices market size is calculated at USD 2.52 billion in 2025 and is forecasted to reach around USD 4.46 billion by 2034, accelerating at a CAGR of 6.52% from 2025 to 2034. The North America market size surpassed USD 1.02 billion in 2024 and is expanding at a CAGR of 6.64% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global hemoglobin A1c testing devices market size accounted for USD 2.37 billion in 2024 and is predicted to increase from USD 2.52 billion in 2025 to approximately USD 4.46 billion by 2034, expanding at a CAGR of 6.52% from 2025 to 2034. The growth of the market is driven by the rising prevalence of diabetes, technological advancements in medical devices, and growing demand for cost-effective monitoring solutions.
The integration of artificial intelligence (AI) algorithms in Hemoglobin A1c (HbA1c) testing devices significantly enhances diagnostic accuracy, optimizes productivity, and enables personalized patient treatment. This facilitates improved treatment strategies and better long-term outcomes for diabetic patients. AI has the ability to interpret data in real time and integrate with electronic health records to streamline patient monitoring. Furthermore, AI supports the development of remote monitoring tools, allowing for home-based testing solutions connected to telemedicine platforms.
The U.S. hemoglobin A1c testing devices market size was exhibited at USD 886.62 million in 2024 and is projected to be worth around USD 1,697.59 million by 2034, growing at a CAGR of 6.68% from 2025 to 2034.
Why Did North America Dominate the Hemoglobin A1c Testing Devices Market in 2024?
North America dominated the hemoglobin A1c testing devices market with the largest share in 2024. This is mainly due to the high prevalence of diabetes in this region, with a constant need for precise HbA1c measurements to ensure proper glycemic control. The region is at the forefront of technological innovations in healthcare, leading to the development of more effective, mobile, and user-friendly testing devices, making them more appealing in clinical practice and point-of-care settings. Government programs, favorable healthcare policies, and reimbursement systems that aim to improve diabetes diagnosis and control also play a major role in market growth. Additionally, North America has a well-developed healthcare system, facilitating easy access to new diagnostic equipment. U.S. healthcare providers prioritize early diagnosis and individual diabetes management, increasing the demand for accurate and rapid testing services.
What Factors Contribute to the Hemoglobin A1c Testing Devices Market Within Asia Pacific?
Asia Pacific is expected to grow at the fastest CAGR during the forecast period. This is mainly due to the rising incidence of diabetes in the region, leading to high demand for diabetes screening and monitoring. The International Diabetes Federation (IDF) estimates that by 2035, there will be approximately 382 million diabetes patients globally, with over 60% in Asia. Growing healthcare spending, increased access to diagnostic facilities, and greater awareness of the importance of early diabetes detection also drive the growth of the market. China and India are major players in the market due to the rising number of diabetics and continuous investments in healthcare infrastructure.
What Opportunities Exist in the European Hemoglobin A1c Testing Devices Market?
Europe is considered to be a significantly growing area. The growth of the market in the region can be attributed to the presence of advanced healthcare infrastructure and a strong focus on patient-centered care. Active management of chronic conditions, including diabetes, has always been a primary concern, and HbA1c testing is crucial for effectively managing and monitoring blood sugar and the disease. The increasing incidence of diabetes further drives the need for high-quality, accurate HbA1c testing devices. Additionally, the well-developed distribution networks and qualified medical workforce in Europe support the widespread use of this diagnostic equipment in hospitals, clinics, and specialized diabetes centers.
Hemoglobin A1c (HbA1c) devices measure the percentage of glycated hemoglobin in circulation to provide vital information about the average blood glucose levels of patients. These devices play a critical role in the diagnosis and monitoring of diabetes, as they allow a medical practitioner to evaluate long-term glycemic control and implement measures to regulate the treatment. These tools promote the proactive management of diabetes by measuring HbA1c to adjust therapies accordingly, enabling customization of therapies. The increasing focus on preventive care, coupled with government efforts to raise diabetes awareness and the growing adoption of regular screening programs, significantly fuels market growth. The integration of HbA1c testing with digital health platforms and mobile health applications is also broadening its scope and effectiveness. The demand for more convenient and less invasive solutions from patients and providers is likely to attract investment in innovation, thereby supporting market growth.
| Report Coverage | Details |
| Market Size by 2034 | USD 4.46 Billion |
| Market Size in 2025 | USD 2.52 Billion |
| Market Size in 2024 | USD 2.37 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 6.52% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Type of Device, Technology, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Increased R&D Efforts
Increased research and development activities are driving the growth of the hemoglobin A1c testing devices market. As the demand for sophisticated diagnostics tools is rising, manufacturers are focusing on innovative devices to meet the evolving demands of healthcare providers and patients alike. Additionally, manufacturers are focusing on developing more compact, portable HbA1c devices like analyzers, as portability has become the preferred choice of healthcare providers seeking convenience and efficiency.
The rising development of new devices with better automation and enhanced accuracy, promising quick turnaround times, and minimal intervention of humans further boosts the growth of the market. Collaborations between medical device manufacturers, healthcare providers, and technology companies can drive innovation and market expansion.
Supply Chain Disruptions and High Cost
Significant challenges in the global hemoglobin A1c testing devices market include major disruptions to supply chains. Accessibility to diagnostics solutions can be reduced due to production delays driven by transportation bottlenecks, hindering the movement of raw materials required. These disruptions caused delays in purchases and availability of HbA1c testing devices, particularly in countries reliant on imported diagnostic equipment and components. Moreover, the initial cost of HbA1c testing devices and the ongoing expenses associated with maintenance can be a barrier, particularly in settings with limited resources.
Rising Demand for Home-Based HbA1c Testing Solutions
The increasing focus on patient-centered care and rising diabetes cases create immense opportunities for home-based HbA1c testing solutions. With more patients seeking convenient, cost-effective, and accessible methods to manage their condition, home A1c testing devices are becoming popular as a viable alternative to traditional lab-based methods. These devices enable individuals to measure their HbA1c at home, eliminating the need for regular clinic visits and improving compliance with routine monitoring.
The pandemic accelerated this shift to home testing as patients and providers sought ways to reduce in-person interactions while maintaining necessary care. This transition is expected to have a long-term impact, driving investment in user-friendly, reliable, and interconnected home testing technologies. Advancements in diagnostic technologies, miniaturization, and the sensitivity of biosensors are likely to enhance the stability of these solutions and their commercial adoption.
Why Did the Point-of-Care Testing Devices Dominate the Market in 2024?
The point-of-care testing devices segment dominated the hemoglobin A1c testing devices market with the largest revenue share in 2024. This is mainly due to the increased demand for rapid diagnosis and timely intervention. POC devices significantly reduce waiting times in hospitals, leading to greater efficiency in the care process and making them highly appealing. There is a growing demand for portable, easy-to-use diagnostic devices, especially in areas with limited access to laboratories.
Further advancements in accuracy and automation, and digital connectivity of POC devices have increased their feasibility. Integration with mobile health applications and electronic health records (EHR) also enhances remote monitoring and management of chronic diseases. The segment's growth is also reinforced due to increased patient preference for rapid and reliable tests in primary care settings and home healthcare.
The laboratory-based testing devices segment is expected to grow at a significant CAGR over the forecast period. Laboratory-based HbA1c tests are known for their high precision and reliability, making them the preferred choice for clinical diagnosis and patient management. Technologies like high-performance liquid chromatography (HPLC) and immunoassay systems have improved test accuracy and processing speed. The growing popularity of automated analyzers has led diagnostic laboratories to invest in these systems to efficiently handle increasing test volumes. Supportive healthcare policies and the expansion of diagnostic infrastructure, particularly in developing markets, also drive segmental growth.
How Does the Immunoassays Segment Dominate the Market?
The immunoassays segment dominated the hemoglobin A1c testing devices market with a major revenue share in 2024. The low cost and quick turnaround time make this method especially popular in point-of-care applications. Immunoassays are widely used in outpatient clinics and diagnostic centers, making them very convenient and accessible for routine diabetes monitoring.
Immunoassays are helpful in identifying other diabetes-related biomarkers like insulin, C-peptide, and beta-cell autoantibodies, which aid in comprehensive diabetes classification and management due to their flexibility. The high adoption rate of immunoassays is also due to their low operational complexity and costs, increasing their usability in most clinical settings.
The high-performance liquid chromatography segment is expected to grow at the fastest rate in the upcoming period. HPLC is considered the gold standard for HbA1c measurement, unmatched in precision, reproducibility, and detailed molecular analysis. HPLC is highly sought after in specialized diabetes clinics, high-quality diagnostic labs, and scientific centers. The increasing demand for standardized, precise, and consistent diagnostic methods is expected to drive the adoption of HPLC systems.
What Made Hospitals & Clinics the Dominant Segment in the HbA1c Testing Devices Market in 2024?
The hospitals & clinics segment dominated the hemoglobin A1c testing devices market with the largest revenue share in 2024. These medical centers are the initial point of contact for most patients needing medical care and are crucial in mass diabetes screening programs and long-term management of glycemic control. Hospitals and clinics have quality laboratory facilities and well-trained healthcare workers.
Government-sponsored awareness programs and health initiatives have also increased diabetes testing in hospitals and clinical settings. Improvements in hospitals and clinics allow effective diabetes management, with HbA1c examinations included in services for chronic illness patients, improving patient outcomes and simplifying treatment plans.
The homecare settings segment is expected to grow at a significant CAGR over the forecast period. This is mainly due to the rising prevalence of diabetes worldwide and the growing demand for patient-centered care, which emphasizes convenience, affordability, and independence. Home hemoglobin A1c testing allows individuals to actively participate in their treatment, regardless of attending medical facilities, and it is more affordable. These innovations are user-friendly and provide consistent and precise results. Digital health platforms, like mobile apps and remote patient monitoring, improve communication with healthcare facilities and provide access to data-driven care at home.
(Source: https://www.selectscience.net)
(Source: https://hemocue.com)
(Source: https://www.finddx.org)
(Source: https://www.medicaldevice-network.com)
By Type of Device
By Technology
By End-User
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
November 2024
April 2025
February 2025
December 2024